Skip to main content
. 2018 Jun 15;9:318. doi: 10.3389/fendo.2018.00318

Figure 5.

Figure 5

Pathological subtype of tumors, proliferative markers, and O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression in aggressive pituitary adenomas and pituitary carcinomas treated with temozolomide. Data from Ref. (77).